Nathanael Gray, PhD, received his doctorate in chemistry from the University of California at Berkeley in 1999. He then moved to the Genomics Institute of the Novartis Research Foundation in San Diego, where, after serving as a staff scientist and group leader of kinase inhibitor chemistry, he was named director of biological chemistry in 2001. Dr. Gray’s research team was responsible for the development of several clinical candidates, including BAF312, which is currently undergoing phase III clinical trials for the treatment of multiple sclerosis. Dr. Gray joined the faculty of Harvard Medical School and the Dana-Farber Cancer Institute to continue his research using synthetic chemistry and functional small molecule discovery to modulate biological pathways important in cancer. His research group has been responsible for the discovery of novel inhibitors of wild-type and mutant forms of EGFR, mTor, Bcr-Abl, Mps1, Erk5, b-Raf and Ephrin kinases.